Syncom Formulation (India) Ltd. (SYNCOMF) Price & Analysis

Compare

5 Followers

SYNCOMF Stock Chart & Stats

₹13.98

-₹0.26(-1.33%)

At close: Jan 08 4:00 PM EST

₹13.98

-₹0.26(-1.33%)

Day’s Range― - ―

52-Week Range₹11.36 - ₹23.46

Previous CloseN/A

Volume2.15M

Average Volume (3M)249.72K

Market Cap

₹11.55B

Enterprise Value₹11.57B

Total Cash (Recent Filing)₹899.28M

Total Debt (Recent Filing)₹0.00

Price to Earnings (P/E)16.8

Beta1.51

Next Earnings

May 28, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.20

Shares Outstanding940,000,000

10 Day Avg. Volume232,913

30 Day Avg. Volume249,719

Financial Highlights & Ratios

PEG Ratio0.27

Price to Book (P/B)4.34

Price to Sales (P/S)3.19

P/FCF Ratio110.11

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Revenue And Margin MomentumAn 86.14% revenue increase year-over-year, with gross margin at 20.80% and net margin at 10.25%, reflects durable demand, improved pricing and operational leverage. Sustained top-line growth and margin expansion support reinvestment, product development and scalable earnings over the next several months.

Very Low Leverage And Strong Equity BaseAn equity ratio of 82.77% and debt-to-equity of 0.01 provide a very low-leverage capital structure and an improving ROE of 14.45%. This structural balance-sheet strength reduces refinancing risk, preserves optionality for capex or M&A, and enhances resilience to sector cycles across a multi-month horizon.

Recovering Free Cash FlowFree cash flow swinging to +134.77 million in 2025 from a prior negative position signals improved cash generation and working-capital management. This recovery bolsters the company’s ability to fund operations, invest in growth or reduce liabilities internally, supporting durable financing flexibility over coming quarters.

Bears Say

Moderate Cash Conversion EfficiencyAn operating cash flow to net income ratio of 0.47 shows earnings convert to cash only moderately. If this conversion rate persists, it can constrain liquidity for inventories, capex or debt servicing, increasing sensitivity to working-capital swings and limiting sustainable internal funding despite positive FCF.

Above-market Volatility (beta)A reported beta of ~1.51 denotes above-market sensitivity, implying the business and reported earnings are more volatile relative to the market. Structurally higher volatility raises financing and planning risks, necessitates larger cash buffers, and can complicate multi-quarter strategic execution.

No Regular Shareholder Cash ReturnsThe stated absence of a dividend yield means the company currently provides no regular cash returns to shareholders. Over time this reduces appeal to income-oriented investors and places greater pressure on management to deliver capital appreciation and demonstrate disciplined allocation of improving cash flows.

Syncom Formulation (India) Ltd. News

Syncom Formulations Faces Rs 1.42 Crore GST Demand and Penalty After Appeal Rejection

Syncom Formulation (India) Ltd. ( ($IN:SYNCOMF) ) has provided an update. Syncom Formulations (India) Ltd. has disclosed that...

2M ago

Syncom Formulations Acquires Strategic Commercial Property in Mumbai

An announcement from Syncom Formulation (India) Ltd. ( ($IN:SYNCOMF) ) is now available. Syncom Formulations (India) Limited has...

3M ago

Syncom Formulations Appoints New Secretarial Auditor

Syncom Formulation (India) Ltd. ( ($IN:SYNCOMF) ) has shared an announcement. Syncom Formulations (India) Limited has announced a...

5M ago

Syncom Formulations Announces 37th AGM and Key Appointments

Syncom Formulation (India) Ltd. ( ($IN:SYNCOMF) ) has provided an update. Syncom Formulations (India) Limited has announced its...

6M ago

SYNCOMF FAQ

What was Syncom Formulation (India) Ltd.’s price range in the past 12 months?

Syncom Formulation (India) Ltd. lowest stock price was ₹11.36 and its highest was ₹23.46 in the past 12 months.

What is Syncom Formulation (India) Ltd.’s market cap?

Syncom Formulation (India) Ltd.’s market cap is ₹11.55B.

When is Syncom Formulation (India) Ltd.’s upcoming earnings report date?

Syncom Formulation (India) Ltd.’s upcoming earnings report date is May 28, 2026 which is in 85 days.

How were Syncom Formulation (India) Ltd.’s earnings last quarter?

Syncom Formulation (India) Ltd. released its earnings results on Feb 12, 2026. The company reported ₹0.201 earnings per share for the quarter, beating the consensus estimate of N/A by ₹0.201.

Is Syncom Formulation (India) Ltd. overvalued?

According to Wall Street analysts Syncom Formulation (India) Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Syncom Formulation (India) Ltd. pay dividends?

Syncom Formulation (India) Ltd. pays a Notavailable dividend of ₹0.03 which represents an annual dividend yield of N/A. See more information on Syncom Formulation (India) Ltd. dividends here

What is Syncom Formulation (India) Ltd.’s EPS estimate?

Syncom Formulation (India) Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Syncom Formulation (India) Ltd. have?

Syncom Formulation (India) Ltd. has 940,000,000 shares outstanding.

What happened to Syncom Formulation (India) Ltd.’s price movement after its last earnings report?

Syncom Formulation (India) Ltd. reported an EPS of ₹0.201 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 0.282%.

Which hedge fund is a major shareholder of Syncom Formulation (India) Ltd.?

Currently, no hedge funds are holding shares in IN:SYNCOMF

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Syncom Formulation (India) Ltd.

Syncom Formulations (India) Limited manufactures, markets, and sells pharmaceutical formulation products in India. It offers various products, including generics, alpha adrenoceptor agonists, analgesics, antipyretics, anti-inflammatory, anti-ulcer agents, antibiotics, antidepressants, antifungals, antihistamines, antimalarial, antiplatelet agents, antiprotozoal, antivirals, bronchodilators, calcium antagonists, cardiac medicines, central nervous stimulants, cephelo sporins, cortico steroids, estrogen, cough suppressants, erectile dysfunction, and electrolite. The company also provides histamines, homeostatic, hypoglycemic, hypolipidaemics, local anesthetics, multivitamins and nutritional supplements, sedative anticonvulsants, stimulants, and sympathomimetic products, as well as products used in the treatment of gout. In addition, it engages in the trading of commodities and renting of properties. Further, the company exports its products. It offers its pharmaceutical formulations products in various dosage forms, such as tablets, capsules, liquids orals, liquid vials, ampoule injections and dry vial injections, dry syrups, ointments, inhalers, and herbals. Syncom Formulations (India) Limited was founded in 1985 and is based in Indore, India.